Search results
Results from the WOW.Com Content Network
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin , like octreotide .
Another peptide known to self-assemble is the octapeptide Lanreotide. This compound is a synthetic analogue of the peptide hormone somatostatin and it is used to treat acromegaly [6] (a condition where the body produced too much growth hormone). In water, Lanreotide self-assembles into monodisperse liquid crystalline nanotubes. The nanotubes ...
In many people with acromegaly, GH levels fall within one hour and headaches improve within minutes after the injection. Octreotide and lanreotide are effective for long-term treatment. Octreotide and lanreotide have also been used successfully to treat people with acromegaly caused by non-pituitary tumors. [citation needed]
Treatments may be aimed at curing the disease or at relieving symptoms . Observation may be feasible for non-functioning low-grade neuroendocrine tumors. If the tumor is locally advanced or has metastasized, but is nonetheless slowly growing, treatment that relieves symptoms may often be preferred over immediate challenging surgeries.
In these cases, the patients may be prescribed expensive autoimmune disease drugs that just manage the symptoms but don't actually treat the cause, according to the doctor.
In other cases, imaging can be performed by labelling a suitable radionuclide to the same peptide as used for therapy. [22] Radionuclides that can be used for imaging include gallium-68, technetium-99m and fluorine-18. [21] Currently used peptides can result in high kidney doses, as the radiopharmaceutical is retained for relatively long ...
Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012 [2] [9] and by the U.S. Food and Drug Administration (FDA) in December 2012. [ 1 ] [ 10 ] Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014, [ 11 ] and had been approved for ...
Progestins (progesterone-like drugs) such as megestrol acetate and medroxyprogesterone acetate have been used for the treatment of hormone-responsive, advanced breast cancer, endometrial cancer, and prostate cancer. Progestins are also used in the treatment of endometrial hyperplasia, a precursor to endometrial adenocarcinoma. The exact ...